Featured Research

from universities, journals, and other organizations

TB Prophylaxis Unnecessary in HIV-Infected People with Anergy, Study Suggests

Date:
July 31, 1997
Source:
National Institute of Allergy and Infectious Diseases
Summary:
HIV-infected patients at high risk for tuberculosis (TB) but without confirmed TB infection do not benefit from preventive treatment with a front-line TB drug, an NIAID-supported study has found. The study is reported in the July 31, 1997 issue of The New England Journal of Medicine.

HIV-infected patients at high risk for tuberculosis (TB) but without confirmed TB infection do not benefit from preventive treatment with a front-line TB drug, a study supported by the National Institute of Allergy and Infectious Diseases (NIAID) has found. The study is reported in the July 31, 1997 issue of The New England Journal of Medicine.

"Clinicians who care for people with HIV/AIDS should take note of this important finding," says NIAID Director Anthony S. Fauci, M.D. "This study suggests that we can make more efficient use of TB prevention resources by focusing on HIV-infected persons with known TB infection or who have close contact with another individual with active TB."

Although only 10 percent of healthy people infected with TB bacteria ever develop active TB disease, co-infection with TB and HIV dramatically increases this risk. A number of studies have shown that daily treatment with the antibiotic isoniazid (INH) significantly reduces TB disease risk in persons known to be co-infected with HIV and TB.

The tuberculin skin test, which involves injecting TB-derived proteins below the skin, is the only method available for diagnosing inactive, or latent, TB infection. Palpable swelling at the site of injection occurs in most TB-infected people with healthy immune systems. However, HIV-infected people with suppressed immune systems often exhibit anergy, a reduced or absent reaction to skin tests for TB as well as other infections. In such persons, TB infection can be masked by a false negative skin test. As a precaution against activation of a possible latent TB infection, in 1991 the Centers for Disease Control and Prevention (CDC) suggested that INH preventive therapy be given to anergic HIV-infected individuals at high risk for TB. High-risk individuals include those who belong to groups, such as homeless persons and those who inject drugs, in which the prevalence of TB infection is at least 10 percent.

To determine the effectiveness of INH prophylaxis in this population, investigators in NIAID's Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) divided more than 500 high-risk HIV-infected people with anergy into groups that received either daily INH or placebo. They found that the number of cases of active TB disease that developed in each group during the six-month study period did not differ significantly.

"Our findings suggest that giving INH to people in this group is probably not warranted," says lead author Fred M. Gordin, M.D., of the Veterans Affairs Medical Center in Washington, D.C. "It would be more appropriate to reserve INH preventive therapy for HIV-infected persons who have a prior history of a positive TB skin test or who have been in recent contact with someone with active TB disease."

In fact, revised guidelines for preventing TB and other opportunistic infections in HIV-infected individuals, developed by the U.S. Public Health Service (PHS) and the Infectious Diseases Society of America, (IDSA) recommend just that: daily INH for persons with positive TB skin tests and for those in close contact with someone known to have active TB. The PHS/IDSA Working Group considered the findings of Dr. Gordin and his colleagues in developing the guidelines, which were published in the June 27, 1997 issue of Morbidity and Mortality Weekly Report.

"The low rates of TB in both the treatment and placebo groups (three cases out of 260 patients, and six cases out of 257 patients, respectively)," says Dr. Gordin, "indicate that TB may be under much better control than in 1991 when the CDC suggested that INH preventive therapy might be useful in anergic patients."

Dr. Gordin adds that in addition to saving the considerable programmatic costs associated with administering prophylactic INH to anergic HIV-infected individuals, a more selective use of INH would allow many people to avoid the known toxic side effects of INH. For example, about 2 percent of persons who take INH develop hepatitis.

The CPCRA is a network of primary care physicians and nurses who work with NIAID staff to design and conduct community-based clinical trials in patients with HIV disease and AIDS. NIAID currently funds 15 CPCRA units in 14 cities throughout the United States.

NIAID is a component of the National Institutes of Health (NIH). NIAID conducts and supports research to prevent, diagnose and treat illnesses such as AIDS and other sexually transmitted diseases, tuberculosis, asthma and allergies. NIH is an agency of the U.S. Department of Health and Human Services.

###

NIAID press releases, fact sheets and other materials are available on the Internet via the NIAID home page at http://www.niaid.nih.gov.


Story Source:

The above story is based on materials provided by National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

National Institute of Allergy and Infectious Diseases. "TB Prophylaxis Unnecessary in HIV-Infected People with Anergy, Study Suggests." ScienceDaily. ScienceDaily, 31 July 1997. <www.sciencedaily.com/releases/1997/07/970731080643.htm>.
National Institute of Allergy and Infectious Diseases. (1997, July 31). TB Prophylaxis Unnecessary in HIV-Infected People with Anergy, Study Suggests. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/1997/07/970731080643.htm
National Institute of Allergy and Infectious Diseases. "TB Prophylaxis Unnecessary in HIV-Infected People with Anergy, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/1997/07/970731080643.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com
How The 'Angelina Jolie Effect' Increased Cancer Screenings

How The 'Angelina Jolie Effect' Increased Cancer Screenings

Newsy (Sep. 19, 2014) Angelina's Jolie's decision to undergo a preventative mastectomy in 2013 inspired many women to seek early screenings for the disease. Video provided by Newsy
Powered by NewsLook.com
The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins